Mucormycosis is any fungal infection caused by fungi in the order Mucorales. Generally, species in the Mucor, Rhizopus, Absidia, and Cunninghamella genera are most often implicated. The disease is often characterized by hyphae growing in and around blood vessels and can be potentially life-threatening in diabetic or severely immunocompromised individuals.
If mucormycosis is suspected, amphotericin B therapy should be immediately administered due to the rapid spread and high mortality rate of the disease. Amphotericin B is usually administered for an additional 4–6 weeks after initial therapy begins to ensure eradication of the infection. After administration of either amphotericin B or posaconazole, surgical removal of the "fungus ball" is indicated. The disease must be monitored carefully for any signs of reemergence.

Market Analysis and Insights: Global Mucormycosis Market
The global Mucormycosis market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Mucormycosis market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Mucormycosis market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Mucormycosis market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Mucormycosis market.

Global Mucormycosis Scope and Market Size
Mucormycosis market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Mucormycosis market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Diagnosis and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Diagnosis
Computed Tomography (CT)
Magnetic resonance imaging (MRI)
Tissue Biopsy
Others

Segment by Application
Hospitals & Clinics
Medical Institutes
Research Organization
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Abbott Laboratories
Biocon
Cadila Pharmaceuticals
Novartis
Merck
Roche
Bristol Myers Squibb
Pfizer